LCK operates with radio waves.
It uses a system producing 350 kH radio waves.

The spots are placed in a specific order and principle.
The depth, angle, and location of the spots are more important.

Radio-wave energy coming out of each spot provides the new form by shrinking collagen fibers in corneal tissue.

Artificial astigmatism, which may occur, can be corrected with a very simple technique at the end of the third month if required.

Application History of the LCK Method in the World

CK method clinical studies for hyperopia treatment, started by the U.S. Food and Drug Administration (FDA) in November 1999, attained approval in 2001.
At the Ophthalmologists Congress (American Society of Cataract and Refractive Surgery (ASCRS)), held in America in April 2000, FDA studies were at least as good as those of the LASIK method.
In May 2001, the FDA started to work on the results of presbyopia (deterioration of nearsighted vision) treatment using the CK method.
On 16 April 2002, the FDA completed these studies and gave approval for hyperopia treatment after age 40.
On 25 August 2003, the FDA gave the first approval for usage of the CK method in presbyopia treatment in the U.S.
By 31 December 2003, 22,491 patients had been treated with the CK method in the U.S.
On 9 February 2004, specialized doctors in an FDA open session declared that the CK method could be the first choice of treatment for presbyopia.
By 31 December 2004, more than 75,000 patients had been treated with the CK method.
On 18 February 2005, the FDA also approved CK operations for patients who had previously had LASIK surgery.
On 4 October 2005, the FDA approved Light Touch CK (LCK), the developed version of the CK method, improving efficiency of this new technique.
By 31 December 2005, more than 150,000 patients had been treated using the LCK method.
All over the world, the method is confidently applied by more than 800 doctors for treatment of hyperopia and nearsighted vision glasses.